Determination of physicochemical properties and degradation kinetics of triamcinolone acetonide palmitate in vitro

Drug Development and Industrial Pharmacy

Volumn 36, Issue 12, 2010, Pages 1469-1476

  Peng, Cuilian ^a   Liu, Cong ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Enzymolysis; Hydrolysis; In vitro; Partition coefficient; Solubility; Triamcinolone acetonide palmitate

Indexed keywords

MEDIUM CHAIN TRIACYLGLYCEROL; PHOSPHATIDYLCHOLINE; PRODRUG; SOYBEAN OIL; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE ACETONIDE PALMITATE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL REACTION KINETICS; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; HYDROLYSIS; LIVER HOMOGENATE; NONHUMAN; PARTITION COEFFICIENT; PH; PHYSICAL CHEMISTRY; PREFORMULATION; RAT; TEMPERATURE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; EMULSIONS; GLUCOCORTICOIDS; HALF-LIFE; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; LIVER; PRODRUGS; RATS; SOLUBILITY; SOLUTIONS; TRIAMCINOLONE ACETONIDE;

EID: 78149364020     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.488645     Document Type: Article

References (41)

1. Abraham G, Demiraj F, Ungemach FR. (2006). Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: A direct pharmacokinetic correlation. J Endocrinol, 191(2):491-6.
2. Ebrahem Q, Minamoto A, Hoppe G, Anand-Apte B, Sears JE. (2006). Triamcinolone acetonide inhibits IL-6- and VEGFinduced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci, 47:4935-41.
3. Bitter C, Suter K, Figueiredo V, Pruente C, Hatz K, Surber C. (2008). Preservative-free triamcinolone acetonide suspension developed for intravitreal injection. J Ocul Pharmacol Ther, 24:62-9.
4. Han YY, Sun W. (2002). An evidence-based review on the use of corticosteroids in peri-operative and critical care. Acta Anaesthesiol Sin, 40:71-9.
5. Möllmann H, Rohdewald P, Schmidt EW, Salomon V, Derendorf H. (1985). Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol, 29:85-9.
6. Doi M, Ishida T, Sugio S, Imagawa T, Inoue M. (1989). Physicochemical properties of dexamethasone palmitate, a high fatty acid ester of an anti-inflammatory drug: Polymorphism and crystal structure. J Pharm Sci, 78(5):417-22.
7. Manjunath K, Reddy JS, Venkateswarlu V. (2005). Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol, 27(2):127.
8. Monika C, Berthold N, Adelheid L, Robert W, Jörg K. (1995). The potential of the prodrug clindamycin palmitate as an implantable slow release form of the antibiotic clindamycin for heart valves. J Control Release, 33:147-53.
9. Goundalkar A, Mezei M. (1984). Chemical modification of triamcinolone acetonide to improve liposomal encapsulation. J Pharm Sci, 73(6):834-45.
10. López GF, Vázquez JM, Gil F, Latoore R, Moreno F, Villalaín J, et al. (1993). Intra-articular therapy of experimental arthritis with a derivative of triamcinolone acetonide incorporated in liposomes. J Pharm Pharmacol, 45(6):576-8.
11. Li P, Hynes SR, Haefele TF, Pudipeddi M, Royce AE, Serajuddin AT. (2009). Development of clinical dosage forms for a poorly water-soluble drug II: Formulation and characterization of a novel solid microemulsion preconcentrate system for oral delivery of a poorly water-soluble drug. J Pharm Sci, 98:1750-64.
12. Giannola L, De CV, Giandalia G, Siragusa MG, Lamartina L. (2008). Synthesis and in vitro studies on a potential dopamine prodrug. Pharmazie, 63(10):704-10.
13. Muñoz-Muriedas J, Perspicace S, Bech N, Guccione S, Orozco M, Luque FJ. (2005). Hydrophobic molecular similarity from MST fractional contributions to the octanol/water partition coefficient. J Comput Aided Mol Des, 19(6):401-19.
14. Capková Z, Vitková Z, Tilandyová J, Cizmárik J. (2005). Preformulation studies of potential drug XIX M: Partition coefficient. Ceska Slov Farm, 54:75-7.
15. Okada F, Kobayashi A, Fujiwara N, Takahashi K. (1999). Bacteriostatic and bactericidal actions of antimicrobial drugs studied by microbial calorimetry. Biocontrol Sci, 4(1):35-9.
16. Sathanandam SA, James VB, Wendy TH, Srinivasa M, Jeffrey WFP. (2006). Characterization of deltamethrin metabolism by rat plasma and liver microsomes. Toxicol Appl Pharmacol, 212:156-66.
17. Zhang Y, Tang X, Liu XL, Li F, Lin X. (2008). Simultaneous determination of three bufadienolides in rat plasma after intravenous administration of bufadienolides extract by ultra performance liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chim Acta, 610(2):224-31.
18. Piper SN, Roehm KD, Boldt J, Odermatt B, Maleck WH, Suttner SW. (2008). Hepatocellular integrity in patients requiring parenteral nutrition: Comparison of structured MCT/LCT vs. a standard MCT/LCT emulsion and a LCT emulsion. Eur J Anaesthesiol, 25(7):557-65.
19. Li F, Wang T, He HB, Tang X. (2008). The properties of bufadienolides- loaded nano-emulsion and submicro-emulsion during lyophilization. Int J Pharm, 349:291-9.
20. Ghebremeskel AN, Vemavarapu C, Lodaya M. (2007). Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: Selection of polymer-surfactant combinations using solubility parameters and testing the processability. Int J Pharm, 328(2):119-29.
21. Strickley RG. (2003). Solubilizing excipients in oral and injectable formulations. Pharm Res, 21(2):201-30.
22. Friberg SE, Wohn CS, Lockwood FE. (1985). The influence of solvent on nonaqueous lyotropic liquid crystalline phase formed by triethanolammonium oleate. J Pharm Sci, 74(7):771-3.
23. Takahashi YI, Underwood BA. (1974). Effect of long and medium chain length lipids upon aqueous solubility of alphatocopherol. Lipids, 9(11):855-9.
24. Ostergaard M, Halberg P. (1999). Intra-articular glucocorticoid injections in joint diseases. Ugeskr Laeger, 161(5):582-6.
25. Benita S, Levy MY. (1993). Submicron emulsions as colloidal drug carriers for intravenous administration: Comprehensive physicochemical characterization. J Pharm Sci, 82:1069-79.
26. Jumaa M, Kleinebudde P, Müller BW. (1999). Physicochemical properties and hemolytic effect of different lipid emulsion formulations using a mixture of emulsifiers. Pharm Acta Helv, 73:293-301.
27. Lu Y, Wang YJ, Tang X. (2008). Formulation and thermal sterile stability of a less painful intravenous clarithromycin emulsion containing vitamin E. Int J Pharm, 346:47-56.
28. Strichartz GR, Sanchez V, Arthur GR, Chafetz R, Martin D. (1990). Fundamental properties of local anesthetics. II. Measured octanol: Buffer partition coefficients and pKa values of clinically used drugs. Anesth Analg, 71:158-70.
29. Hillery AM, Lloyd AW, Swarbrick J. (2001). Drug delivery and targeting for pharmacists and pharmaceutical scientists. London, UK: CRC Press, 21.
30. Schaupp K, Polzer J, Kerbl J, Lanthaler K, Davis SS, Washington C. (1996). Stable emulsion suitable for pharmaceutical administration, the production thereof and emulsion for pharmaceutical use. US patent 5496818.
31. Zhang DN, Ildiko MK, John PS. (2008). Locating the rate-determining step(s) for three-step hydrolase-catalyzed reactions with dynafit. Biochim Biophys Acta, 84:827-33.
32. Gupta VD. (1983). Stability of triamcinolone acetonide solutions as determined by high-performance liquid chromatography. J Pharm Sci, 72(12):1453-6.
33. Laura C, Catherine D, Karen G, Gregory L, Patrick C, Pierre C. (2005). Phospholipid hydrolysis in a pharmaceutical emulsion assessed by physicochemical parameters and a new analytical method. Eur J Pharm Biopharm, 61:69-76.
34. Liu Y, Lin X, Tang X. (2009). Lipid emulsions as a potential delivery system for ocular use of azithromycin. Drug Dev Ind Pharm, 35(7):887-96.
35. Portilla-Rivera O, Torrado A, Domínguez JM, Moldes AB. (2008). Stability and emulsifying capacity of biosurfactants obtained from lignocellulosic sources using Lactobacillus pentosus. J Agric Food Chem, 56(17):8074-80.
36. Tamilvanan S. (2004). Oil-in-water lipid emulsions: Implications for parenteral and ocular delivering systems. Prog Lipid Res, 43(6):489-533.
37. Nakanishi S, Tominaga T, Yamanaka I, Higo T, Shibata T (1996). Injection and injection kit containing omeprazole and its analogs. European patent EP0652751.
38. Landowski CP, Lorenzi PL, Song X, Amidon GL. (2006). Nucleoside ester prodrug substrate specificity of liver carboxylesterase. J Pharmacol Exp Ther, 316(2):572-80.
39. Aboul-Fadl T, Fouad EA. (1996). Synthesis and in vitro investigations of nalidixic acid amides of amino acid esters as prodrugs. Pharmazie, 51(1):30-3.
40. Wenzel U, Jouvenal K, Tripier D, Ziegler K. (1995). Cyclic somatostatin analogs bind specifically to pI 6.1 carboxylesterase of rat liver cells. Biochem Pharmacol, 49(4):479-87.
41. Leggas M, Rinehart J, Zhu D, Jordan S, Horn J, Goswami M, et al. (2006). Nanoparticle-dexamethasone palmitate enhances anticancer agent toxicity. http://www.aapsj.org/abstracts/AM-2006/AAPS2006-003693.pdf [accessed May 09, 2006].